Dennis Kim, MD, PhD

My research is aiming to develop projects of: 1) biomarker discovery using genomics in leukemias and allogeneic stem cell transplantation; and 2) clinical research in chronic myeloid leukemia and graft-versus-host disease after allogeneic stem cell transplantation.

I have also been involved in multiple exome sequencing projects in acute myleoid leukemia (AML) with normal karyotype and secondary AML progressed from antecedent hematologic malignancies, as well as chronic myeloid leukemia (CML). My future direction of genomic research is to integrate multi-omics platforms to investigate leukemia genomes, thus dissecting clonal structures in a refined way.

Not only in translational research, but also in the clinical research field, I have shown significant progress in three ways: 1) clinical database registry; 2) retrospective studies using the database; and 3) generation of prospective clinical trials in CML and in graft-versus-host disease (GVHD) and other post-transplant complications after allogeneic stem cell transplantation.  First of all, I developed a clinical database of allogeneic transplant patients (especially for GVHD and post-transplant complications) and CML patients (especially for treatment outcomes after tyrosine kinase inhibitor therapy). Secondly, I have participated in multiple ongoing clinical retrospective studies generated from the registry database. Thirdly, I am involved in  multiple clinical trials. Currently, I am the principal investigator of a pivotal Canadian tyrosine kinase inhibitor (TKI) discontinuation clinical trial and am also a chair of the correlative part of this trial, entitled "Treatment-free Remission Accomplished with Dasatinib (TRAD)". This is the first Canadian TKI discontinutation trial for the management of CML.
Eur J Haematol. 2019 Jun;102(6):486-493
Prem S, Atenafu EG, Al-Shaibani Z, Loach D, Law A, Lam W, Michelis FV, Thyagu S, Kim DDH, Howard Lipton J, Kumar R, Viswabandya A
J Clin Med. 2019 Feb 24;8(2):
Warburton DER, Bredin SSD, Shellington EM, Cole C, de Faye A, Harris J, Kim DD, Abelsohn A
Eur J Haematol. 2019 Jan 31;:
Pasic I, Da'na W, Lam W, Law A, Lipton JH, Viswabandya A, Kim DD, Thyagu S, Messner HA, Michelis FV
Biol Blood Marrow Transplant. 2019 Jan 14;:
Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, Messner HA
Leukemia. 2018 Dec 16;:
Park JH, Woo YM, Youm EM, Hamad N, Won HH, Naka K, Park EJ, Park JH, Kim HJ, Kim SH, Kim HJ, Ahn JS, Sohn SK, Moon JH, Jung CW, Park S, Lipton JH, Kimura S, Kim JW, Kim DDH
Med Decis Making. 2018 Oct;38(7):767-777
Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE, Ganiats TG, Sanders GD
Leuk Res. 2018 Sep 05;73:67-75
Savoie ML, Bence-Bruckler I, Huebsch LB, Lalancette M, Hillis C, Walker I, Lipton JH, Forrest DL, Kim DDH
Biol Blood Marrow Transplant. 2018 Aug 25;:
Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin...
Blood. 2018 Aug 14;:
Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Choi SH, Lee JY, Tyndel MS, Shin MG, Lee YJ, Sohn SK, Park SK, Zhang Z, Kim HJ, Kim DDH

Pages